Related Experiment Video

Updated: Mar 16, 2026

Paramyxoviruses for Tumor-targeted Immunomodulation: Design and Evaluation Ex Vivo
12:42

Paramyxoviruses for Tumor-targeted Immunomodulation: Design and Evaluation Ex Vivo

Published on: January 7, 2019

10.4K

Recombinant mumps virus as a cancer therapeutic agent

Arun Ammayappan1, Stephen J Russell2, Mark J Federspiel1

  • 1Department of Molecular Medicine, Mayo Clinic , Rochester, Minnesota, USA.

Molecular Therapy Oncolytics
|August 25, 2016
PubMed

Insights

Mumps virus shows promise as an oncolytic agent for cancer treatment. Researchers developed recombinant mumps viruses demonstrating antitumor activity in vitro and in animal models.

Area of Science:

  • Virology
  • Oncology
  • Gene Therapy

Background:

  • Mumps virus (Paramyxoviridae family) was previously investigated as an oncolytic agent in human cancer clinical trials in Japan four decades ago.
  • Early studies indicated significant antitumor activity, but interest waned with the slow development of oncolytic virotherapy.
  • Recent advancements in oncolytic virotherapy have prompted renewed investigation into mumps virus for cancer treatment.

Purpose of the Study:

  • To resurrect and explore the potential of the Urabe strain of mumps virus as an oncolytic agent.
  • To develop a reverse genetics system for the Urabe strain mumps virus.
  • To construct and characterize recombinant mumps viruses with enhanced therapeutic potential.

Main Methods:

  • Obtained the Urabe strain mumps virus from Osaka University, Japan.
  • Developed a reverse genetics system for the Urabe strain.
  • Constructed and characterized recombinant mumps viruses expressing additional transgenes.

Main Results:

  • Demonstrated oncolytic activity of recombinant mumps viruses against tumor cell lines in vitro.
  • Showed preliminary efficacy in pilot animal tumor models.
  • Established a platform for developing genetically modified mumps viruses for cancer therapy.

Conclusions:

  • Recombinant mumps viruses exhibit oncolytic potential against cancer cells.
  • The Urabe strain of mumps virus serves as a viable candidate for oncolytic virotherapy development.
  • Further research is warranted to optimize and translate these findings into clinical applications for cancer treatment.

More Related Videos

A Nonviral Approach to Generate Transient Chimeric Antigen Receptor T Cells Using mRNA for Cancer Immunotherapy09:56

A Nonviral Approach to Generate Transient Chimeric Antigen Receptor T Cells Using mRNA for Cancer Immunotherapy

Published on: February 21, 2025

1.5K
Induction of Invasive Transitional Cell Bladder Carcinoma in Immune Intact Human MUC1 Transgenic Mice: A Model for Immunotherapy Development11:02

Induction of Invasive Transitional Cell Bladder Carcinoma in Immune Intact Human MUC1 Transgenic Mice: A Model for Immunotherapy Development

Published on: October 30, 2013

21.9K

Related Concept Videos

Cancer Vaccines01:30

Cancer Vaccines

Cancer treatment vaccines are a rapidly evolving field that offers a promising approach to immunotherapy. Unlike traditional vaccines that prevent diseases, cancer treatment vaccines are designed to treat existing cancers by stimulating the immune system to recognize and attack cancer cells.
Cancer vaccines come in two categories: preventive (prophylactic) and treatment (active). Preventive vaccines, such as the Human Papillomavirus (HPV) vaccine, protect against viruses that cause certain...
1.2K
Mouse Models of Cancer Study02:43

Mouse Models of Cancer Study

Mice have long served as models for studying human biology and pathology because of their phylogenetic and physiological similarity with humans. They are also easy to maintain and breed in the laboratory, and hence, many inbred strains are now available for research. Studies on mice have contributed immeasurably to our understanding of cancer biology.
The development of transgenic, knockout, and knock-in mice has led to an exponential increase in their use as model organisms in research,...
6.7K
Rous Sarcoma Virus (RSV) and Cancer01:03

Rous Sarcoma Virus (RSV) and Cancer

Rous Sarcoma virus or RSV was discovered by F. Peyton Rous in the year 1911 as a filterable transmissible agent that could cause tumors in chickens. He won a Nobel Prize for this discovery in 1966. His experiments clearly demonstrated that some cancers could be caused by infectious agents and led to the discovery of many more cancer-causing viruses in animals as well as humans.
RSV is a retrovirus that contains two copies of a plus-strand  RNA genome. Its genome consists of four main open...
6.5K
Tumor Immunotherapy01:27

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
2.1K
Mechanisms of Retrovirus-induced Cancers01:51

Mechanisms of Retrovirus-induced Cancers

Retroviruses are RNA viruses that have been shown to cause cancers in diverse species, including chickens, mice, cats, and monkeys. The RNA genomes of these viruses are first reverse-transcribed into single and then double-stranded DNA (dsDNA) copies. This dsDNA called proviral DNA then integrates into the host genome. Subsequently, the host cell transcribes the proviral DNA in concert with the chromosomal DNA. This leads to the production of viral RNA and proteins that assemble at the host...
7.2K